Pharmala Biotech签署最终授权协议,授予Jupiter Neurosciences Ala-002在美国的独家权益

美股速递
Jul 21

Pharmala Biotech已正式签署一项最终授权协议。根据该协议,Jupiter Neurosciences将获得候选药物Ala-002在美国市场的独家开发与商业化权利。

此举标志着Jupiter Neurosciences在其神经科学产品管线布局上迈出了关键一步。通过获得Ala-002的独家授权,该公司有望加强其在特定治疗领域的市场地位。协议的财务条款及具体细节未在本次公告中披露。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10